Proteina , a bio company based on protein big data, announced on the 19th that it has submitted a securities report to the Financial Services Commission for listing on KOSDAQ and is actively pursuing an initial public offering (IPO).
A total of 1.5 million shares will be issued through this public offering, and the desired public offering price band is 11,000 won to 14,000 won. The total public offering amount is expected to be 16.5 billion won to 21 billion won, and the market capitalization after listing is expected to be around 119 billion won to 151 billion won. The demand forecast for institutional investors will be conducted for 5 business days from June 11 to 17, and the general subscription will be conducted on June 23 and 24. The listing underwriter is Korea Investment & Securities.
Proteina is a company established in 2015 as a faculty startup at the Korea Advanced Institute of Science and Technology (KAIST), and was the first in the world to commercialize the platform technology 'SPID (Single-molecule Protein Interaction Detection)' that can analyze protein-protein interactions (PPI) at the single molecule level. Based on this platform, Proteina provides services that support the entire process of new drug development, including biomarker development and antibody design. Its main product groups are 'PPI PathFinder' for next-generation biomarker development and 'PPI Landscape' for antibody optimization and design.
The funds raised through this public offering will be used to advance the SPID platform, develop new biomarkers, expand joint development of biobetters and protein new drugs, and develop an AI-based antibody new drug platform. In addition, the company is pursuing expansion of the sales and service organization in its Boston, USA office, and is also considering acquiring a local clinical diagnostic certification facility (CLIA Lab).
CEO Yoon Tae-young said, “This KOSDAQ listing is the result of our SPID platform’s technological prowess being recognized by multinational pharmaceutical companies, and we plan to use this as an opportunity to accelerate our entry into the global antibody design and new drug development market.” He added, “We will further strengthen our R&D and production capabilities to grow into a comprehensive bio company based on protein big data, including diagnosis, antibody optimization, and AI new drug design.”
You must be logged in to post a comment.